

NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

Non-Hodgkin's Lymphoma (NHL)

7th Guideline Development Group (GDG) meeting

26th January 2015

51 Chenies Mews, London

GROUP MEMBERSHIP & ACTION LIST

GDG Members	
David Linch (DL) (Chair)	Christopher McNamara (CM) (Clinical Lead)
Ian Chau (IC)	Bhuey Sharma (BS)
Kim Linton (KL)	Jennifer Wimperis (JW)
Graham Collins (GC)	Karl Peggs (KP)
Tessa Somerville (TS)	Jacqueline Green (JG)
Katharine Robinson (KR)	Morag Day (MD)
Andrew Jack (AJ)	Gillian Howard-Jones (GHJ)
NCC-C staff	
Coral McCarthy (CMc)	Laura Bunting (LB)
Andrew Champion (AC)	Mia Schmidt-Hansen (MSH)
Debbie Fitzsimmons (DF)	Kateryna Onishchenko (KO)
NICE staff	
Julia Bidonde (JB)	Katie Perryman Ford (KPF)
Apologies	
Peter Hoskin (PH)	John Graham (JG)
Sabine Berendse (SB)	

REPORTS OF DISCUSSION AT THE MEETING

1. Introductions

DL welcomed everyone and thanked them for attending the 7th meeting of the NHL GDG.

Apologies for absence were received from Peter Hoskin, John Graham and Sabine Berendse.

A welcome was given to Julia Bidonde, a technical analyst from NICE who was attending as an observer.

2. Declarations of interest

The following declarations of interest were made prior the meeting:

- DL received reimbursement of travel expenses and conference registration from Gilead for attending the American Society of Haematology in San Francisco. This interest was categorised as personal pecuniary, non specific meaning that DL can declare and participate in discussions on all topics as expenses were not beyond a reasonable amount.
- GC received an honorarium from Gilead for giving a talk on the use of idealasib in double refractory follicular lymphoma. This interest was categorised as personal pecuniary, specific. GC can declare and participate in discussions on all topics as idelalisib is being

investigated by NICE TA's and therefore will not be included as an intervention in the guideline.

- GC received an honorarium from Celgene for attending an advisory board on the use of lenalidomide in relapsed/refractory mantle cell lymphoma. This interest was categorised as personal pecuniary, specific. GC can declare and participate in discussions on all topics as lenalidomide is being investigated by NICE TA's and therefore will not be included as an intervention in the guideline.
- GC received an honorarium from Takeda for giving a talk to the Scottish Lymphoma Group on the use of brentuximab in Hodgkin's lymphoma. This interest was categorised as personal pecuniary, non-specific meaning that GC can declare and participate in discussions on all topics as the guideline does not include Hodgkin's lymphoma.
- IC informed the GDG that he had attended a conference last month that he needed to declare and agreed to email CMc the details.

The GDG were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that the necessary action can be taken.

3. Discussions

The GDG discussed the evidence and agreed the draft recommendations and LETR paragraph for topics, A, D1 &, D2.

The GDG reviewed and agreed the changes to the research recommendation and LETR paragraph for topic L1 and the recommendation and LETR paragraph for topic N.

4. Date and venue of next meeting

DL thanked the GDG for their input to the meeting and reminded them that the next meeting would be on **Friday 27th March 2015 at NICE, Manchester.**